Relevance of Additional Immunohistochemical Markers in the Differential Diagnosis of Small B-Cell Lymphomas: A Case-Control Study

Ozcan, Muhit; YÜKSEL, Seher; KAYGUSUZ, GULSAH; KUZU, ISINSU; kivrak, hale; ateş, can; Merter, Mustafa

doi:10.4274/tjh.galenos.2021.2021.0349

Relevance of Additional Immunohistochemical Markers in the Differential Diagnosis of Small B-Cell Lymphomas: A Case-Control Study

Hale Kıvrak, (Ankara Üniversitesi Tıp Fakültesi, Patoloji Anabilim Dalı, Ankara, Türkiye)

Seher Yüksel, (Ankara Üniversitesi Tıp Fakültesi, Patoloji Anabilim Dalı, Ankara, Türkiye)

Can Ateş, (Aksaray Üniversitesi Tıp Fakültesi Biyoistatistik ve Tıp Bilişimi Anabilim Dalı, Aksaray, Türkiye)

Mustafa Merter, (Fırat Üniversitesi Tıp Fakültesi Hematoloji Anabilim Dalı, Elazığ, Türkiye)

Gülşah Kaygusuz, (Ankara Üniversitesi Tıp Fakültesi, Patoloji Anabilim Dalı, Ankara, Türkiye)

Muhit Özcan, (Ankara Üniversitesi Tıp Fakültesi Hematoloji Anabilim Dalı, Ankara, Türkiye)

Işınsu Kuzu (Ankara Üniversitesi Tıp Fakültesi, Patoloji Anabilim Dalı, Ankara, Türkiye)

Turkish Journal of Hematology

0 0

Yıl: 2022 Cilt: 39 Sayı: 3 Sayfa Aralığı: 178 - 187 Metin Dili: İngilizce DOI: 10.4274/tjh.galenos.2021.2021.0349 İndeks Tarihi: 02-10-2022

Relevance of Additional Immunohistochemical Markers in the Differential Diagnosis of Small B-Cell Lymphomas: A Case-Control Study

Öz:

Objective: Clinical and pathological differential diagnosis of small B-cell lymphomas (SBCLs) is still controversial and may be difficult due to their overlapping morphology, phenotype, and differentiation to plasma cells. We aimed to examine the expression of the immune receptor translocation-associated protein 1 (IRTA1), myeloid cell nuclear differentiation antigen (MNDA), lymphoid enhancer-binding factor-1 (LEF1), and stathmin 1 (STMN1) markers in SBCL cases involving different sites that may have plasma cell differentiation. Materials and Methods: We studied 154 tissue samples with lymphoma involvement from 116 patients and evaluated the staining distribution of the markers. Expressions were evaluated in 21 chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), 7 follicular lymphoma (FL), 14 nodal marginal zone lymphoma, 17 extranodal marginal zone lymphoma, 55 splenic marginal zone lymphoma, 22 marginal zone lymphoma-not otherwise specified, and 18 lymphoplasmacytic lymphoma/Waldenström macroglobulinemia cases by immunohistochemistry. Results: The results confirmed that LEF1 was the most sensitive and specific marker for CLL/SLL and STMN1 was the most sensitive and specific marker for FL (p<0.001). MNDA and IRTA1 were useful markers to distinguish marginal zone lymphomas. Conclusion: Our results suggest that LEF1 for CLL/SLL and STMN1 for FL are reliable markers. LEF1, MNDA, STMN1, and IRTA1 are helpful with other routinely used immunohistochemical markers in a diagnostic algorithm considering their limitations.

Anahtar Kelime:

Küçük B-Hücreli Lenfomalarda Ek İmmünohistokimyasal Belirteçlerin Ayırıcı Tanıdaki Yeri: Bir Olgu-Kontrol Çalışması

Öz:

Amaç: Küçük B-hücreli lenfomaların (SBCL) klinik ve patolojik ayırıcı tanısı halen tartışmalıdır ve örtüşen morfolojileri, fenotipleri ve plazma hücresine farklılaşmaları nedeni ile zorluk yaratabilir. Bu çalışmada plazma hücre farklılaşması gösteren farklı lokalizasyonlardaki SBCL’lerde, immün reseptör translokasyonu ilişkili protein 1 (IRTA1), myeloid hücre farklılaşma antijeni (MNDA), lenfoid güçlendirici bağlama faktörü-1 (LEF1) ve stathmin 1 (STMN1) belirteçlerinin ekspresyonu araştırılmıştır. Gereç ve Yöntemler: Çalışmada 116 hastadan alınmış olan 154 farklı dokuda belirteçlerin boyanma dağılımları incelenmiştir. Belirteçlerin ekspresyonları 21 kronik lenfositik lösemi/küçük lenfositik lenfoma (KLL/SLL), 7 foliküler lenfoma (FL), 14 nodal marjinal zon lenfoma, 17 ekstranodal marjinal zon lenfoma, 55 splenik marjinal zon lenfoma, 22 marjinal zon lenfoma-başka türlü sınıflandırılamamış ve 18 lenfoplazmasitik lenfoma örneğinde immünhistokimyasal olarak değerlendirilmiştir. Bulgular: Sonuçlar, LEF1’in KLL/SLL için ve STMN1’in FL için hassas ve spesifik belirteçler olduğunu (p değeri <0,001); MNDA ve IRTA- 1’in marjinal zon lenfomalarını ayırt etmek için yararlı belirteçler olduğunu gösterdi. Sonuç: Sonuçlarımız LEF1’in KLL/SLL için ve STMN1’in FL için güvenilir belirleyiciler olduğunu göstermektedir. LEF1, MNDA, STMN1 ve IRTA1, tanısal bir algoritma içinde kısıtlılıkları dikkate alınarak kullanıldığında, rutin olarak kullanılan diğer immünohistokimyasal belirteçlere yardımcıdır.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Arber DA, Hasserjian RP, Le Beau MM, Orazi A, Siebert R. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th Edition. Lyon, IARC, 2017.
2. Challagundla P, Jorgensen JL, Kanagal-Shamanna R, Gurevich I, Pierson DM, Ferrajoli A, Reyes SR, Medeiros LJ, Miranda RN. Utility of quantitative flow cytometry immunophenotypic analysis of CD5 expression in small B-cell neoplasms. Arch Pathol Lab Med 2014;138:903-909.
3. Du MQ. MALT lymphoma: genetic abnormalities, immunological stimulation and molecular mechanism. Best Pract Res Clin Haematol 2017;30:13-23.
4. Spina V, Rossi D. Molecular pathogenesis of splenic and nodal marginal zone lymphoma. Best Pract Res Clin Haematol 2017;30:5-12.
5. Briggs RC, Kao WY, Dworkin LL, Briggs JA, Dessypris EN, Clark J. Regulation and specificity of MNDA expression in monocytes, macrophages, and leukemia/B lymphoma cell lines. J Cell Biochem 1994;56:559-567.
6. Miranda RN, Briggs RC, Shults K, Kinney MC, Jensen RA, Cousar JB. Immunocytochemical analysis of MNDA in tissue sections and sorted normal bone marrow cells documents expression only in maturing normal and neoplastic myelomonocytic cells and a subset of normal and neoplastic B lymphocytes. Hum Pathol 1999;30:1040-1049.
7. Kanellis G, Roncador G, Arribas A, Mollejo M, Montes-Moreno S, Maestre L, Campos-Martin Y, Rios Gonzalez JL, Martinez-Torrecuadrada JL, Sanchez- Verde L, Pajares R, Cigudosa JC, Martin MC, Piris MA. Identification of MNDA as a new marker for nodal marginal zone lymphoma. Leukemia 2009;23:1847-1857.
8. van den Brand M, Mathijssen JJ, Garcia-Garcia M, Hebeda KM, Groenen PJ, Falini B, Serrano S, van Krieken JH. Immunohistochemical differentiation between follicular lymphoma and nodal marginal zone lymphoma-- combined performance of multiple markers. Haematologica 2015;100:e358- 360.
9. Agematsu K, Hokibara S, Nagumo H, Komiyama A. CD27: A memory B-cell marker. Immunol Today 2000;21:204-206.
10. Lohneis P, Wienert S, Klauschen F, Ullrich A, Anagnostopoulos I, Johrens K. Marginal zone lymphomas with monocytoid morphology express T-bet and are associated with a low number of T cells in extranodal locations. Leuk Lymphoma 2014;55:143-148.
11. Franco V, Florena AM, Ascani S, Paulli M, Salvato M, Pileri SA. CD27 distinguishes two phases in bone marrow infiltration of splenic marginal zone lymphoma. Histopathology 2004;44:381-386.
12. Khan NI, Bendall LJ. Role of WNT signaling in normal and malignant hematopoiesis. Histol Histopathol 2006;21:761-774.
13. Reya T, O’Riordan M, Okamura R, Devaney E, Willert K, Nusse R, Grosschedl R. Wnt signaling regulates B lymphocyte proliferation through a LEF-1 dependent mechanism. Immunity 2000;13:15-24.
14. Tandon B, Peterson L, Gao J, Nelson B, Ma S, Rosen S, Chen YH. Nuclear overexpression of lymphoid-enhancer-binding factor 1 identifies chronic lymphocytic leukemia/small lymphocytic lymphoma in small B-cell lymphomas. Mod Pathol 2011;24:1433-1443.
15. Menter T, Dirnhofer S, Tzankov A. LEF1: a highly specific marker for the diagnosis of chronic lymphocytic B cell leukaemia/small lymphocytic B cell lymphoma. J Clin Pathol 2015;68:473-478.
16. Ikeda JI, Kohara M, Tsuruta Y, Nojima S, Tahara S, Ohshima K, Kurashige M, Wada N, Morii E. Immunohistochemical analysis of the novel marginal zone B-cell marker IRTA1 in malignant lymphoma. Hum Pathol 2017;59:70-79.
17. Falini B, Agostinelli C, Bigerna B, Pucciarini A, Pacini R, Tabarrini A, Falcinelli F, Piccioli M, Paulli M, Gambacorta M, Ponzoni M, Tiacci E, Ascani S, Martelli MP, Dalla Favera R, Stein H, Pileri SA. IRTA1 is selectively expressed in nodal and extranodal marginal zone lymphomas. Histopathology 2012;61:930- 941.
18. Marafioti T, Copie-Bergman C, Calaminici M, Paterson JC, Shende VH, Liu H, Baia M, Ramsay AD, Agostinelli C, Briere J, Clear A, Du MQ, Piccaluga PP, Masir N, Nacheva EP, Sujobert P, Shanmugam K, Grogan TM, Brooks SP, Khwaja A, Ardeshna K, Townsend W, Pileri SA, Haioun C, Linch D, Gribben JG, Gaulard P, Isaacson PG. Another look at follicular lymphoma: immunophenotypic and molecular analyses identify distinct follicular lymphoma subgroups. Histopathology 2013;62:860-875.
19. Verdanet E, Dereure O, Rene C, Tempier A, Benammar-Hafidi A, Gallo M, Frouin E, Durand L, Gazagne I, Costes-Martineau V, Cacheux V, Szablewski V. Diagnostic value of STMN1, LMO2, HGAL, AID expression and 1p36 chromosomal abnormalities in primary cutaneous B cell lymphomas. Histopathology 2017;71:648-660.
20. Bob R, Falini B, Marafioti T, Paterson JC, Pileri S, Stein H. Nodal reactive and neoplastic proliferation of monocytoid and marginal zone B cells: an immunoarchitectural and molecular study highlighting the relevance of IRTA1 and T-bet as positive markers. Histopathology 2013;63:482-498.
21. Swerdlow SH, Kuzu I, Dogan A, Dirnhofer S, Chan JK, Sander B, Ott G, Xerri L, Quintanilla-Martinez L, Campo E. The many faces of small B cell lymphomas with plasmacytic differentiation and the contribution of MYD88 testing. Virchows Arch 2016;468:259-275.
22. Metcalf RA, Monabati A, Vyas M, Roncador G, Gualco G, Bacchi CE, Younes SF, Natkunam Y, Freud AG. Myeloid cell nuclear differentiation antigen is expressed in a subset of marginal zone lymphomas and is useful in the differential diagnosis with follicular lymphoma. Hum Pathol 2014;45:1730- 1736.
23. Lin P, Hao S, Handy BC, Bueso-Ramos CE, Medeiros LJ. Lymphoid neoplasms associated with IgM paraprotein: a study of 382 patients. Am J Clin Pathol 2005;123:200-205.
24. van den Brand M, van Krieken JH. Recognizing nodal marginal zone lymphoma: recent advances and pitfalls. A systematic review. Haematologica 2013;98:1003-1013.
25. Duong Van Huyen JP, Molina T, Delmer A, Audouin J, Le Tourneau A, Zittoun R, Bernadou A, Diebold J. Splenic marginal zone lymphoma with or without plasmacytic differentiation. Am J Surg Pathol 2000;24:1581-1592.
26. Gutierrez A Jr, Arendt BK, Tschumper RC, Kay NE, Zent CS, Jelinek DF. Differentiation of chronic lymphocytic leukemia B cells into immunoglobulin secreting cells decreases LEF-1 expression. PLoS One 2011;6:e26056.
27. Wang Z, Cook JR. IRTA1 and MNDA expression in marginal zone lymphoma: utility in differential diagnosis and implications for classification. Am J Clin Pathol 2019;151:337-343.
28. Manohar V, Peerani R, Tan B, Gratzinger D, Natkunam Y. Myeloid cell nuclear differentiation antigen (MNDA) positivity in primary follicles: potential pitfall in the differential diagnosis with marginal zone lymphoma. Appl Immunohistochem Mol Morphol 2020;28:384-388.
29. Joshi AD, Hegde GV, Dickinson JD, Mittal AK, Lynch JC, Eudy JD, Armitage JO, Bierman PJ, Bociek RG, Devetten MP, Vose JM, Joshi SS. ATM, CTLA4, MNDA, and HEM1 in high versus low CD38 expressing B-cell chronic lymphocytic leukemia. Clin Cancer Res 2007;13:5295-5304.
30. Nutt SL, Hodgkin PD, Tarlinton DM, Corcoran LM. The generation of antibody-secreting plasma cells. Nat Rev Immunol 2015;15:160-171. 31. Agematsu K, Nagumo H, Yang FC, Nakazawa T, Fukushima K, Ito S, Sugita K, Mori T, Kobata T, Morimoto C, Komiyama A. B cell subpopulations separated by CD27 and crucial collaboration of CD27+ B cells and helper T cells in immunoglobulin production. Eur J Immunol 1997;27:2073-2079.
32. Falini B, Tiacci E, Pucciarini A, Bigerna B, Kurth J, Hatzivassiliou G, Droetto S, Galletti BV, Gambacorta M, Orazi A, Pasqualucci L, Miller I, Kuppers R, Dalla-Favera R, Cattoretti G. Expression of the IRTA1 receptor identifies intraepithelial and subepithelial marginal zone B cells of the mucosa- associated lymphoid tissue (MALT). Blood 2003;102:3684-3692.

APA	kivrak h, YÜKSEL S, ateş c, Merter M, KAYGUSUZ G, Ozcan M, KUZU I (2022). Relevance of Additional Immunohistochemical Markers in the Differential Diagnosis of Small B-Cell Lymphomas: A Case-Control Study. , 178 - 187. 10.4274/tjh.galenos.2021.2021.0349
Chicago	kivrak hale,YÜKSEL Seher,ateş can,Merter Mustafa,KAYGUSUZ GULSAH,Ozcan Muhit,KUZU ISINSU Relevance of Additional Immunohistochemical Markers in the Differential Diagnosis of Small B-Cell Lymphomas: A Case-Control Study. (2022): 178 - 187. 10.4274/tjh.galenos.2021.2021.0349
MLA	kivrak hale,YÜKSEL Seher,ateş can,Merter Mustafa,KAYGUSUZ GULSAH,Ozcan Muhit,KUZU ISINSU Relevance of Additional Immunohistochemical Markers in the Differential Diagnosis of Small B-Cell Lymphomas: A Case-Control Study. , 2022, ss.178 - 187. 10.4274/tjh.galenos.2021.2021.0349
AMA	kivrak h,YÜKSEL S,ateş c,Merter M,KAYGUSUZ G,Ozcan M,KUZU I Relevance of Additional Immunohistochemical Markers in the Differential Diagnosis of Small B-Cell Lymphomas: A Case-Control Study. . 2022; 178 - 187. 10.4274/tjh.galenos.2021.2021.0349
Vancouver	kivrak h,YÜKSEL S,ateş c,Merter M,KAYGUSUZ G,Ozcan M,KUZU I Relevance of Additional Immunohistochemical Markers in the Differential Diagnosis of Small B-Cell Lymphomas: A Case-Control Study. . 2022; 178 - 187. 10.4274/tjh.galenos.2021.2021.0349
IEEE	kivrak h,YÜKSEL S,ateş c,Merter M,KAYGUSUZ G,Ozcan M,KUZU I "Relevance of Additional Immunohistochemical Markers in the Differential Diagnosis of Small B-Cell Lymphomas: A Case-Control Study." , ss.178 - 187, 2022. 10.4274/tjh.galenos.2021.2021.0349
ISNAD	kivrak, hale vd. "Relevance of Additional Immunohistochemical Markers in the Differential Diagnosis of Small B-Cell Lymphomas: A Case-Control Study". (2022), 178-187. https://doi.org/10.4274/tjh.galenos.2021.2021.0349

APA	kivrak h, YÜKSEL S, ateş c, Merter M, KAYGUSUZ G, Ozcan M, KUZU I (2022). Relevance of Additional Immunohistochemical Markers in the Differential Diagnosis of Small B-Cell Lymphomas: A Case-Control Study. Turkish Journal of Hematology, 39(3), 178 - 187. 10.4274/tjh.galenos.2021.2021.0349
Chicago	kivrak hale,YÜKSEL Seher,ateş can,Merter Mustafa,KAYGUSUZ GULSAH,Ozcan Muhit,KUZU ISINSU Relevance of Additional Immunohistochemical Markers in the Differential Diagnosis of Small B-Cell Lymphomas: A Case-Control Study. Turkish Journal of Hematology 39, no.3 (2022): 178 - 187. 10.4274/tjh.galenos.2021.2021.0349
MLA	kivrak hale,YÜKSEL Seher,ateş can,Merter Mustafa,KAYGUSUZ GULSAH,Ozcan Muhit,KUZU ISINSU Relevance of Additional Immunohistochemical Markers in the Differential Diagnosis of Small B-Cell Lymphomas: A Case-Control Study. Turkish Journal of Hematology, vol.39, no.3, 2022, ss.178 - 187. 10.4274/tjh.galenos.2021.2021.0349
AMA	kivrak h,YÜKSEL S,ateş c,Merter M,KAYGUSUZ G,Ozcan M,KUZU I Relevance of Additional Immunohistochemical Markers in the Differential Diagnosis of Small B-Cell Lymphomas: A Case-Control Study. Turkish Journal of Hematology. 2022; 39(3): 178 - 187. 10.4274/tjh.galenos.2021.2021.0349
Vancouver	kivrak h,YÜKSEL S,ateş c,Merter M,KAYGUSUZ G,Ozcan M,KUZU I Relevance of Additional Immunohistochemical Markers in the Differential Diagnosis of Small B-Cell Lymphomas: A Case-Control Study. Turkish Journal of Hematology. 2022; 39(3): 178 - 187. 10.4274/tjh.galenos.2021.2021.0349
IEEE	kivrak h,YÜKSEL S,ateş c,Merter M,KAYGUSUZ G,Ozcan M,KUZU I "Relevance of Additional Immunohistochemical Markers in the Differential Diagnosis of Small B-Cell Lymphomas: A Case-Control Study." Turkish Journal of Hematology, 39, ss.178 - 187, 2022. 10.4274/tjh.galenos.2021.2021.0349
ISNAD	kivrak, hale vd. "Relevance of Additional Immunohistochemical Markers in the Differential Diagnosis of Small B-Cell Lymphomas: A Case-Control Study". Turkish Journal of Hematology 39/3 (2022), 178-187. https://doi.org/10.4274/tjh.galenos.2021.2021.0349